GLP-1 drugs mimic a hormone in the intestinal tract to balance the body’s blood sugar levels. And while GLP-1 drugs such as ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Direct-to-consumer healthcare startup Ro announced Wednesday that its platform will now offer cheaper single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lillywhich ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

Shelby Knowles / Bloomberg / Getty Images Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.